NASDAQ · NTRA
Natera, Inc.
$436.00+$11.58 (+2.73%)
Natera, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.32% below the high.
Loading market information…
NASDAQ · ILMN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Illumina, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.24% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Illumina, Inc.’s next earnings report is currently expected on Feb 4, 2027, with estimated earnings per share of $1.50. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Illumina, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 |
|---|
| Jul 31, 2025 |
| $1.19+16.67% vs estimate |
| $1.06B-0.56% vs estimate |
| Q1 2025 | May 8, 2025 | $0.97+3.19% vs estimate | $1.04B+1.52% vs estimate |
|---|
| Q4 2024 | Feb 6, 2025 | $0.86-6.52% vs estimate | $1.10B+3.0% vs estimate |
|---|
THE ANALYST VIEW
50 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 11 contributors · Median target $260.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$436.00+$11.58 (+2.73%)
Natera, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.32% below the high.
$185.31+$2.72 (+1.49%)
Guardant Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.0% below the high.
$81.55-$2.07 (-2.48%)
10x Genomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.68% below the high.
$114.84+$0.84 (+0.74%)
BillionToOne, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.66% below the high.
$17.93-$0.06 (-0.33%)
NeoGenomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.02% below the high.
$71.02+$6.33 (+9.79%)
GeneDx Holdings Corp.’s quoted price sits in the lower half of its reported 52-week range, 58.44% below the high.
$15.93-$0.08 (-0.47%)
Personalis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.7% below the high.
$2.90+$0.07 (+2.47%)
Pacific Biosciences of California, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.7% below the high.
